Last updated: 02/21/2025 11:02:06
A Phase III, double-blind study to assess safety and efficacy of an RSV Maternal unadjuvanted vaccine, in pregnant women and infants born to vaccinated mothersGRACE
EudraCT ID
EU CT Number
Not applicable
Trial status
Terminated (halted prematurely)
Terminated (halted prematurely)
Trial overview
Official title: A Phase III, randomized, double-blind, placebo-controlled multi-country study to demonstrate efficacy of a single dose of unadjuvanted RSV Maternal vaccine, administered IM to pregnant women 18 to 49 years of age, for prevention of RSV associated LRTIs in their infants up to 6 months of age
Trial description: The purpose of this study was to evaluate the ability of a single dose of the investigational RSV Maternal vaccine, administered intramuscularly (IM) to pregnant women aged 18-49 years, in good general maternal health, in preventing medically assessed RSV associated Lower Respiratory Tract Illnesses (LRTIs) in infants born to vaccinated mothers. The study also evaluated the safety of the investigational RSV Maternal vaccine both in vaccinated mothers and in their corresponding infant.Following a recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV MAT 009), GSK made the decision to stop enrolment and vaccination in the study. Ongoing study participants at that time continued to be monitored as part of the study.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Number of infant participants with medically assessed, RSV-associated lower respiratory tract illnesses (LRTIs) of any severity and RSV-associated severe LRTIs from birth to Day 181 post-birth
Timeframe: From birth to Day 181 post-birth
Number of infant participants with at least one serious adverse event (SAE) from birth to Day 181 post-birth
Timeframe: From birth to Day 181 post-birth
Number of infant participants with at least one adverse event (AE) leading to study withdrawal from birth to Day 181 post-birth
Timeframe: From birth to Day 181 post-birth
Number of infant participants with at least one medically attended AE (MAE) from birth to Day 181 post-birth
Timeframe: From birth to Day 181 post-birth
Number of infant participants with at least one SAE from birth to Day 366 post-birth
Timeframe: From birth to Day 366 post-birth
Number of infant participants with at least one AE leading to study withdrawal from birth to Day 366 post-birth
Timeframe: From birth to Day 366 post-birth
Number of infant participants with at least one MAE from birth to Day 366 post-birth
Timeframe: From birth to Day 366 post-birth
Secondary outcomes:
Number of infant participants with RSV-associated hospitalizations from birth to Day 181 post-birth
Timeframe: From birth to Day 181 post-birth
Number of infant participants with all-cause LRTIs from birth to Day 181 post-birth
Timeframe: From birth to Day 181 post-birth
Number of infant participants with all-cause LRTIs with hospitalization from birth to Day 181 post-birth
Timeframe: From birth to Day 181 post-birth
Number of infant participants with medically assessed, RSV-associated severe LRTIs from birth to Day 366 post-birth
Timeframe: From birth to Day 366 post-birth
Number of infant participants with medically assessed, RSV-associated LRTIs of any severity from birth to Day 366 post-birth
Timeframe: From birth to Day 366 post-birth
Number of infant participants with medically assessed, RSV-associated severe LRTIs for RSV subtype A and RSV subtype B separately from birth to Day 181 post-birth
Timeframe: From birth to Day 181 post-birth
Number of infant participants with medically assessed, RSV-associated LRTIs of any severity for RSV subtype A and RSV subtype B separately from birth to Day 181 post-birth
Timeframe: From birth to Day 181 post-birth
Number of infant participants with medically assessed, RSV-associated severe LRTIs from birth to Day 121 post-birth
Timeframe: From birth to Day 121 post-birth
Number of infant participants with medically assessed, RSV-associated LRTIs of any severity from birth to Day 121 post-birth
Timeframe: From birth to Day 121 post-birth
Number of infant participants with all-cause pneumonia from birth to Day 181 post-birth
Timeframe: From birth to Day 181 post-birth
Number of infant participants with RSV-associated hospitalizations from birth to Day 366 post-birth
Timeframe: From birth to Day 366 post-birth
Number of maternal participants with RSV-associated medically attended RTIs (RSV-MA-RTIs) from study intervention administration (Day 1) to Day 181 post-delivery
Timeframe: From study intervention administration (Day 1) to Day 181 post-delivery
RSV-A neutralizing antibody titers for maternal participants at Day 1, at Day 31 and at delivery
Timeframe: At Day 1 (before study intervention administration), at Day 31 and at delivery
RSV-A neutralizing antibody titers for infant participants at delivery or within 72 hours after birth
Timeframe: At delivery or within 72 hours after birth
RSV-A neutralizing antibody titers for infant participants at Day 43 post-birth
Timeframe: At Day 43 post-birth
RSV-A neutralizing antibody titers for infant participants at Day 121 post-birth
Timeframe: At Day 121 post-birth
RSV-A neutralizing antibody titers for infant participants at Day 181 post-birth
Timeframe: At Day 181 post-birth
RSV MAT immunoglobulin G (IgG)-specific antibody concentrations for maternal participants at delivery
Timeframe: At delivery
RSV MAT IgG-specific antibody concentrations for infant participants at delivery or within 72 hours after birth
Timeframe: At delivery or within 72 hours after birth (only if no cord blood sample could be obtained at delivery)
Geometric mean ratio (GMR) between cord blood and maternal RSV MAT immunoglobulin G (IgG)-specific antibody concentrations
Timeframe: At delivery (for maternal participants) or within 72 hours after birth (for infant participants, only if no cord blood could be obtained)
Number of maternal participants with any solicited administration site events from Day 1 to Day 7 included
Timeframe: From Day 1 to Day 7 included
Number of maternal participants with any solicited systemic events from Day 1 to Day 7 included
Timeframe: From Day 1 to Day 7 included
Number of maternal participants with any unsolicited AEs from Day 1 to Day 30 included
Timeframe: From Day 1 to Day 30 included
Number of maternal participants with at least one SAE from Day 1 to Day 181 post-delivery
Timeframe: From Day 1 to Day 181 post-delivery
Number of maternal participants with at least one AE leading to study withdrawal from Day 1 to Day 181 post-delivery
Timeframe: From Day 1 to Day 181 post-delivery
Number of maternal participants with at least one all-cause MA-RTI from Day 1 to Day 181 post-delivery
Timeframe: From Day 1 to Day 181 post-delivery
Number of maternal participants with at least one MAE from Day 1 to Day 42 post-delivery
Timeframe: From Day 1 to Day 42 post-delivery, an average of 2 months
Number of maternal participants with pregnancy outcomes from Day 1 to Day 42 post-delivery
Timeframe: From Day 1 to Day 42 post-delivery, an average of 2 months
Number of maternal participants with pregnancy-related adverse events of special interest (AESIs) from Day 1 to Day 42 post-delivery
Timeframe: From Day 1 to Day 42 post-delivery, an average of 2 months
Number of infant participants with neonatal AESIs from birth to Day 42 post-birth
Timeframe: From birth to Day 42 post-birth, an average of 2 months
Interventions:
Biological/vaccine: RSV MAT
Drug: Placebo
Enrollment:
11194
Observational study model:
Not applicable
Primary completion date:
2023-14-06
Time perspective:
Not applicable
Clinical publications:
Peyman Banooni, Bernard Gonik, Cristina Epalza, Osvaldo Reyes, Shabir A Madhi, Grace Devota Gomez-Go, Khalequ Zaman, Conrado Juan Llapur, Eduardo López-Medina, Thorsten Stanley, Anu Kantele, Li-Min Huang, Marisa Márcia Mussi-Pinhata, Jonas Dewulf, Joanne M Langley, Claudia Seidl, Martin Ota, Martha Kirabo, Bruno Anspach, Ilse Dieussaert, Ouzama Henry, Joon Hyung Kim, Marta Picciolato. Efficacy, immunogenicity, and safety of an investigational maternal respiratory syncytial virus prefusion F protein-based vaccine. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2025-Jan-29; doi:10.1093/cid/ciaf033 http://dx.doi.org/ciaf03310.1093/cid/ciaf033
PMID: 39879629
DOI: 10.1093/cid/ciaf033
Medical condition
Respiratory Syncytial Virus Infections
Product
GSK3888550A
Collaborators
Not applicable
Study date(s)
November 2020 to June 2023
Type
Interventional
Phase
3
Participation criteria
Sex
Female
Age
18 - 49 Years
Accepts healthy volunteers
Yes
- Maternal participants
- Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- Maternal participants
- Medical conditions
Inclusion and exclusion criteria
Inclusion criteria:
- Maternal participants
- Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- Participants who give written or witnessed/thumb printed informed consent after the study has been explained, and before any study specific procedures are performed, as per local regulations regulatory requirements.
- Age 18 to 49 years, inclusive, at the time of study intervention.
- Pre-pregnancy BMI 17.0 to 39.9 kg/m2, inclusive.
- In good general maternal health as established by medical history and clinical examination before entering into the study.
- Singleton pregnancy (including instances where the singleton pregnancy derives from a vanishing twin syndrome).
- At 24^0/7 to 34^0/7 weeks of gestation at the time of study vaccination (Visit 1), as established by:
- last menstrual period (LMP) date corroborated by first or second trimester ultrasound examination (U/S) i.e. at or before 28 weeks of gestation.
- 1st or 2nd trimester U/S only, if LMP is unknown/uncertain
- Certain LMP, corroborated by an U/S performed after 28 weeks of gestation is also acceptable.
- No fetal genetic abnormalities (based on genetic testing, if performed).
- No significant congenital malformations, as assessed by fetal anomaly ultrasound scan conducted at or beyond 18 weeks of gestation.
- Willing to provide cord blood.
- Who do not plan to give their child for adoption.
- Who plan to reside in the study area for at least one year after delivery.
- Willing to have the infant followed-up after delivery for a period of 12 months. Infant participants
- Live-born from the study pregnancy.
- If required per local regulations/guidelines, re-signed (confirmed) written or witnessed/thumb printed informed consent for study participation of the infant obtained from the infant’s mother and/or father and/or LAR, before performing any study specific procedure. OR, if permitted by local regulation, documented verbal consent for infant’s participation obtained from the parent(s)/LAR(s) at birth, followed by written consent obtained by (or before) Visit 2-newborn.
Exclusion criteria:
- Maternal participants Medical conditions
- History of allergic disease or reactions likely to be exacerbated by any component of the RSV vaccine
- Hypersensitivity to latex
- Significant complications in the current pregnancy:
- Gestational hypertension unless blood pressure it is controlled and maintained in the normal range (<140mmHg and <90mmHg) through diet and/or antihypertensive medications
- Gestational diabetes not controlled by medication, diet and/or exercise
- Pre-eclampsia
- Eclampsia
- Intrauterine Growth Restriction/Fetal Growth Restriction
- Placenta previa
- Placental abruption, placenta accreta/percreta/increta, chorioamnionitis or any abnormalities that can impair the maternal-fetal circulation
- Polyhydramnios
- Oligohydramnios
- Preterm labour or history of preterm labour in the current pregnancy
- Any intervention to prevent preterm delivery or medical treatment for suspected preterm delivery, including administration of systemic corticosteroids for fetal lung maturation
- Cholestasis
- Other pregnancy-related complications (per investigator’s judgement)
- Significant structural abnormalities of the uterus or cervix
- History of 2 or more prior stillbirths or neonatal deaths/history of 2 or more preterm births at ≤34 weeks gestation/3 or more consecutive spontaneous abortions
- Known HIV infection (as per serological tests performed during the current pregnancy)
- Known or suspected HBV or HCV infection
- Known or suspected infection during the current pregnancy with Toxoplasma, Parvovirus B19, Syphilis, Zika, Rubella, Varicella, CMV or primary genital Herpes Simplex
- Active infection with tuberculosis
- Known or suspected impairment of the immune system
- Current autoimmune disorder for which the participant has received immune-modifying therapy within 6 months before study vaccination, or plans administration through delivery
- Lymphoproliferative disorder or malignancy within 5 years before study vaccination
- Acute or chronic clinically significant abnormality or poorly controlled pre-existent co-morbidities or any other clinical conditions that might pose additional risk to the participant due to participation in the study
- Any conditions that may interfere with participant’s ability to comply with study procedures or receipt of prenatal care
- Any condition which would increase the risks of study participation to the unborn infant Prior/Concomitant therapy
- Prior receipt of an RSV vaccine in the current pregnancy
- Use of any investigational/non-registered product other than the study vaccine/product as described below, or planned use during the period :
- For a drug, vaccine or medical device: from 29 days before the dose of study vaccine
- For immunoglobulins: 3 months before the dose of study vaccine/product. The exception to this is investigational products administered in the setting of a pandemic which may be allowed following delivery
- Planned administration/administration of any vaccine from 29 days before the dose of study vaccine or planned administration through delivery, except:
- Seasonal influenza vaccines, tetanus vaccines, dTpa/Tdap – alone vaccines, dTpa/Tdap vaccines that also contain other antigens, Hepatitis B vaccines, and COVID-19 vaccines all of which may be administered according to standard of care ≥15 days before or after study vaccination
- Administration of immunoglobulins (except anti-Rh0D IG, which may be administered at any time), blood products or plasma derivatives within 3 months before study vaccination or planned administration through delivery
- Administration of immune-modifying therapy within 6 months before the study vaccination, or planned administration through delivery. This includes but is not limited to:
- Azathioprine, mycophenolate mofetil, 6-mercaptopurine, cyclosporine, tacrolimus, monoclonal or polyclonal antibodies
- Prednisone ≥5 mg/day or equivalent for ≥14 days; Inhaled, intra-articular/intra-bursal and topical steroids are allowed
- Corticosteroids administered for fetal lung maturation Prior/Concurrent clinical study experience
- Concurrently participating in another clinical study, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product Other exclusions
- Alcoholism or substance use disorder within the past 24 months based on DSM-5 criteria
- A local condition that precludes injection of the study vaccine/product or precludes assessment of local reactogenicity
- Consanguinity of maternal participant and her partner (second degree cousins or closer)
- Any study personnel or their immediate dependants, family or household members Infant participants
- Concurrently participating in another clinical study, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product
- Any condition which would increase the risks of study participation to the infant
- Child in care.
Trial location(s)
Location
GSK Investigational Site
Hendersonville, TN, United States, 29708
Status
Study Complete
Location
GSK Investigational Site
Boadilla del Monte Madrid, Spain, 28660
Status
Study Complete
Location
GSK Investigational Site
Papatoetoe Auckland, New Zealand, 1701
Status
Study Complete
Location
GSK Investigational Site
Clermont-Ferrand Cedex 1, France, 63100
Status
Study Complete
Location
GSK Investigational Site
San Miguel de TucumAn, Argentina, T4000IHE
Status
Study Complete
Location
GSK Investigational Site
Grand Island, NE, United States, 68803
Status
Study Complete
Location
GSK Investigational Site
Ciudad AutOnoma de Buenos Aire, Argentina, C1141ACG
Status
Study Complete
Location
GSK Investigational Site
SAo JosE do Rio Preto, Brazil, 15090-000
Status
Study Complete
Location
GSK Investigational Site
Santo Domingo Este, Dominican Republic, N/A
Status
Study Complete
Study documents
Study report synopsis
Available language(s): English
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Terminated (halted prematurely)
Actual primary completion date
2023-14-06
Actual study completion date
2023-14-06
Plain language summaries
Summary of results in plain language
Available language(s): English, Bangladeshi Bangla (Bangladesh), Bengali, Dutch (Belgium), Finnish, French (Belgium), French (Canadian), German (Belgium), Hindi, Italian, Kannada, Korean, Malayalam, Marathi, Portuguese (Brazil), Spanish (Argentina), Spanish (Mexico), Spanish, Spanish (United States), Swedish (Finland), Tagalog, Thai, Chinese (Traditional), Tswana, Zulu, French
To view plain language summaries on trialsummaries.com click here.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website